Literature DB >> 29675553

A potential strategy for treating atherosclerosis: improving endothelial function via AMP-activated protein kinase.

Feng Gao1, Jiemei Chen1, Haibo Zhu2.   

Abstract

Endothelial dysfunction is caused by many factors, such as dyslipidemia, endoplasmic reticulum (ER) stress, and inflammation. It has been demonstrated that endothelial dysfunction is the initial process of atherosclerosis. AMP-activated protein kinase (AMPK) is an important metabolic switch that plays a crucial role in lipid metabolism and inflammation. However, recent evidence indicates that AMPK could be a target for atherosclerosis by improving endothelial function. For instance, activation of AMPK inhibits the production of reactive oxygen species induced by mitochondrial dysfunction, ER stress, and NADPH oxidase. Moreover, activation of AMPK inhibits the production of pro-inflammatory factors induced by dyslipidemia and hyperglycemia and restrains production of perivascular adipose tissue-released adipokines. AMPK activation prevents endothelial dysfunction by increasing the bioavailability of nitric oxide. Therefore, we focused on the primary risk factors involved in endothelial dysfunction, and summarize the features of AMPK in the protection of endothelial function, by providing signaling pathways thought to be important in the pathological progress of risk factors.

Entities:  

Keywords:  AMP-activated protein kinase; atherosclerosis; autophagy; cardiovascular diseases; inflammation

Mesh:

Substances:

Year:  2018        PMID: 29675553     DOI: 10.1007/s11427-017-9285-1

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  12 in total

1.  MiRNA-122-5p inhibitor abolishes angiotensin II-mediated loss of autophagy and promotion of apoptosis in rat cardiofibroblasts by modulation of the apelin-AMPK-mTOR signaling.

Authors:  Mei Yang; Juan-Juan Song; Xin-Chun Yang; Guang-Zhen Zhong; Jiu-Chang Zhong
Journal:  In Vitro Cell Dev Biol Anim       Date:  2022-02-07       Impact factor: 2.416

2.  Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram.

Authors:  Gemma Caterina Maria Rossi; Luigia Scudeller; Chiara Lumini; Federica Bettio; Erica Picasso; Giulio Ruberto; Aba Briola; Alessandra Mirabile; Alessia Paviglianiti; Gian Maria Pasinetti; Paolo Emilio Bianchi
Journal:  Sci Rep       Date:  2020-06-26       Impact factor: 4.379

Review 3.  AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases.

Authors:  Qingguo Lu; Xuan Li; Jia Liu; Xiaodong Sun; Thomas Rousselle; Di Ren; Nanwei Tong; Ji Li
Journal:  Biosci Rep       Date:  2019-02-15       Impact factor: 3.840

Review 4.  AMPK: a balancer of the renin-angiotensin system.

Authors:  Jia Liu; Xuan Li; Qingguo Lu; Di Ren; Xiaodong Sun; Thomas Rousselle; Ji Li; Jiyan Leng
Journal:  Biosci Rep       Date:  2019-09-03       Impact factor: 3.840

Review 5.  Role of Endothelial Dysfunction in Cardiovascular Diseases: The Link Between Inflammation and Hydrogen Sulfide.

Authors:  Hai-Jian Sun; Zhi-Yuan Wu; Xiao-Wei Nie; Jin-Song Bian
Journal:  Front Pharmacol       Date:  2020-01-21       Impact factor: 5.810

Review 6.  Improvement Effect of Metformin on Female and Male Reproduction in Endocrine Pathologies and Its Mechanisms.

Authors:  Alexander O Shpakov
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-08

7.  Inhibition of LOXL1-AS1 alleviates oxidative low-density lipoprotein induced angiogenesis via downregulation of miR-590-5p mediated KLF6/VEGF signaling pathway.

Authors:  Xuan Cheng; Zhiwei Liu; Haifeng Zhang; Yajun Lian
Journal:  Cell Cycle       Date:  2021-07-31       Impact factor: 5.173

Review 8.  Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis.

Authors:  Michał Wiciński; Karol Górski; Eryk Wódkiewicz; Maciej Walczak; Magdalena Nowaczewska; Bartosz Malinowski
Journal:  Int J Mol Sci       Date:  2020-03-25       Impact factor: 5.923

9.  The Protective Effect of Bosentan against Atherosclerosis in Apolipoprotein E-Deficient Mice Is Mediated by miRNA-21.

Authors:  Xiaona Xu; Zhiqiang Zhao; Guangping Li
Journal:  Biomed Res Int       Date:  2019-12-05       Impact factor: 3.411

Review 10.  GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review.

Authors:  Yusaku Mori; Takanori Matsui; Tsutomu Hirano; Sho-Ichi Yamagishi
Journal:  Int J Mol Sci       Date:  2020-02-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.